Literature DB >> 7877144

Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo-[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TlBO) derivatives. 4.

W Ho1, M J Kukla, H J Breslin, D W Ludovici, P P Grous, C J Diamond, M Miranda, J D Rodgers, C Y Ho, E De Clercq.   

Abstract

In previous papers, we have described the discovery of a new series of compounds, 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1 H)- ones, TlBO (1 and 1a), with potent anti-HIV-1 activity and the synthesis of analogues to better define the structure-activity relationships (SAR) in terms of changes in substituents at the N-6 position and variations of the five-membered urea ring as well as the seven-membered diazepine ring. This paper describes the synthesis of TlBO analogues with various substitutents on the aromatic ring and their SAR in terms of anti-HIV-1 properties. Substituents on the 8-position furnished the most rewarding results and gave a large improvement in potency versus the parent compound. These included halogen, thiomethyl, and methyl. Analogues like 8-cyano, -methoxy, and -acetylene were equipotent, while 8-amino, -acetylamino, -dimethylamino, and -nitro were inactive (Table 1). Substituents at the 9-position tended to have little effect on activity, and 10-substituents decreased activity. The 8-chloro compound 6a with IC50 = 0.0043 microM is currently under clinical development.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7877144     DOI: 10.1021/jm00005a006

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors.

Authors:  S Hannongbua; P Pungpo; J Limtrakul; P Wolschann
Journal:  J Comput Aided Mol Des       Date:  1999-11       Impact factor: 3.686

2.  Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase.

Authors:  G Tachedjian; M Orlova; S G Sarafianos; E Arnold; S P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

3.  Multi-Site λ-dynamics for simulated Structure-Activity Relationship studies.

Authors:  Jennifer L Knight; Charles L Brooks
Journal:  J Chem Theory Comput       Date:  2011-09-13       Impact factor: 6.006

4.  Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

Authors:  Ila R Singh; John E Gorzynski; Daria Drobysheva; Leda Bassit; Raymond F Schinazi
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

5.  Validating CHARMM parameters and exploring charge distribution rules in structure-based drug design.

Authors:  Jennifer L Knight; Charles L Brooks
Journal:  J Chem Theory Comput       Date:  2009       Impact factor: 6.006

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.